SCHEMBL14730878

SCHEMBL14730878

FC(F)(F)c1cccc(-c2cnc3ccccc3n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
RAB9A P51151 8/20 0.60
ATR Q13535 1/20 0.52
IDO1 P14902 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
JAK2 O60674 2/20 0.50
PIK3CD O00329 1/20 0.50
PIK3CA P42336 1/20 0.50
PIK3CG P48736 1/20 0.50
TP53 P04637 1/20 0.50
STAT1 P42224 1/20 0.50
CTSS P25774 1/20 0.49
BCHE P06276 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
KMO O15229 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
SCN2A Q99250 1/20 0.48
JAK3 P52333 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15110565 0.84 NPC1 (0.60) NPC1RAB9ASMN1; SMN2JAK2TP53
SCHEMBL30139976 0.82 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BCHEKMT2A
SCHEMBL1303359 0.82 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BCHEKMT2A
SCHEMBL20032700 0.81 NPC1 (0.55) NPC1RAB9ASMN1; SMN2BCHEALDH1A1
SCHEMBL20032699 0.81 TLR9 (0.60) NPC1RAB9ASMN1; SMN2BCHEALDH1A1
SCHEMBL1416671 0.79 CTSS (0.54) NPC1RAB9AIDO1SMN1; SMN2TP53
SCHEMBL29746381 0.79 CTSS (0.54) NPC1RAB9AIDO1SMN1; SMN2TP53
SCHEMBL15112605 0.79 BCHE (0.68) NPC1RAB9ASMN1; SMN2JAK2TP53
SCHEMBL15111910 0.78 NPC1 (0.70) NPC1RAB9ASMN1; SMN2JAK2TP53
SCHEMBL12938493 0.78 ADORA2A (0.60) IDO1CTSSADORA2AADORA1SCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744788-B1 BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-10-19 EP disclosed
US-9126976-B2 Substituted benzopiperazines as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2015-09-08 US disclosed
US-9126976-B2 Substituted benzopiperazines as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2015-09-08 US disclosed
US-20140357632-A1 BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS MERCK SHARP & DOHME LLC 2014-12-04 US disclosed
US-20140357632-A1 BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS MERCK SHARP & DOHME LLC 2014-12-04 US disclosed
WO-2013028382-A1 BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357632-A1 BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS CETP, MTTP, HDLBP NPC1 9/4885RAB9A 4638/4885ATR 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.